Algert Global LLC Purchases 10,909 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Algert Global LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 34.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,157 shares of the company's stock after purchasing an additional 10,909 shares during the period. Algert Global LLC owned about 0.14% of Medpace worth $14,006,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MEDP. Pallas Capital Advisors LLC boosted its stake in Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock valued at $1,086,000 after acquiring an additional 2,101 shares during the last quarter. Barclays PLC lifted its stake in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC grew its holdings in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after purchasing an additional 844 shares during the period. SYM FINANCIAL Corp purchased a new stake in Medpace in the fourth quarter worth $320,000. Finally, Tokio Marine Asset Management Co. Ltd. purchased a new position in shares of Medpace during the 4th quarter valued at $9,335,000. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

NASDAQ MEDP traded down $2.14 during trading hours on Friday, reaching $298.67. 71,204 shares of the stock traded hands, compared to its average volume of 345,566. The stock has a 50 day simple moving average of $307.46 and a two-hundred day simple moving average of $328.80. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The company has a market cap of $8.58 billion, a price-to-earnings ratio of 23.65, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter in the previous year, the company posted $3.20 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares in the company, valued at $904,856.36. This represents a 36.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 20.30% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MEDP shares. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Leerink Partners started coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price on the stock. Leerink Partnrs upgraded Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Truist Financial dropped their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday, April 23rd. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.